BCAL Diagnostics Lands National Cancer Test Rollout Via Two Major Pathology Giants
BCAL Diagnostics has announced a significant acceleration in the BCAL Avantect Blood Tests Rollout (ASX: BDX), securing dual pathology partnerships that provide national coverage for its pancreatic and ovarian cancer detection tests. The company’s Avantect products are now available through selected Sonic Healthcare collection centres across New South Wales, Victoria and Queensland, whilst a new agreement with Healius Pathology Network extends access nationally.
This expansion follows the initial launch of Avantect tests in January 2026 at Sydney Breast Clinic, marking a transition from single-site pilot to nationwide availability through two of Australia’s largest pathology providers. The partnerships enable clinicians to order tests through established collection infrastructure, eliminating the need for new systems or processes.
What Avantect tests detect and why early detection matters
Avantect is a cell-free DNA-based blood test designed to support the early detection of pancreatic and ovarian cancers in patients identified as being at elevated risk. Cell-free DNA testing analyses fragments of genetic material that tumours release into the bloodstream, providing a non-invasive method to detect cancer signals without requiring tissue samples.
The focus on pancreatic and ovarian cancers addresses a critical clinical need. Both cancer types typically present limited symptoms in early stages and are often diagnosed at advanced stages when treatment options are more limited. Pancreatic cancer, in particular, has one of the lowest five-year survival rates amongst major cancers, making early detection capabilities particularly valuable for patient outcomes.
The test is specifically designed for elevated-risk patients rather than general population screening, positioning it as a supportive diagnostic tool for clinicians managing high-risk cohorts.
How the technology works
The latest generation of the Avantect test incorporates three key technological components:
- Genomic analysis: Examines DNA sequences to identify cancer-associated genetic changes
- Epigenomic analysis: Detects chemical modifications to DNA that can indicate cancer development
- Machine learning: Combines both data types through algorithms to enhance diagnostic capability and accuracy
When big ASX news breaks, our subscribers know first
Strategic value of pathology partnerships
The dual partnership approach leverages established national collection infrastructure, enabling BCAL to scale distribution without building proprietary collection networks. Sonic Healthcare and Healius represent extensive pathology networks with existing patient touchpoints and clinician relationships across Australia.
For healthcare providers, the integration means Avantect tests can be ordered through the same workflows used for standard pathology requests. This reduces adoption friction and allows clinicians to incorporate the tests into existing patient management protocols without operational changes.
The announcement notes this expands BCAL’s existing collaboration with Sonic Healthcare, which previously supported the company’s BREASTEST plus product for breast cancer screening in women with dense breasts.
Shane Ryan, CEO, BCAL Diagnostics
“Clinicians can now begin ordering the tests for their patients using an established national collection network.”
| Partnership | Coverage | Status |
|---|---|---|
| Sonic Healthcare | NSW, VIC, QLD | Now available |
| Healius Pathology Network | National | New agreement |
| Sydney Breast Clinic | Sydney | Launched January 2026 |
The pathology partnerships reduce go-to-market capital requirements compared to building proprietary collection infrastructure, whilst simultaneously providing immediate national reach through networks with established patient volumes.
BCAL’s expanding diagnostic portfolio
The Avantect rollout forms part of a broader multi-product strategy targeting different cancer types through blood-based diagnostics. BCAL holds an exclusive licence for Australia and New Zealand through ClearNote Health Inc., a US-based precision diagnostics company, covering multiple Avantect products.
The company’s current and pipeline portfolio includes:
- BREASTEST plus: Breast cancer rule-out test for women with dense breast tissue, used alongside mammography
- Avantect Pancreatic: Now available nationally for elevated-risk patients
- Avantect Ovarian: Now available nationally for elevated-risk patients
- Avantect multi-cancer: Part of licensed portfolio representing future expansion opportunity
This multi-product approach provides diversified revenue pathways across different oncology segments whilst demonstrating a platform capability in blood-based cancer diagnostics. The existing BREASTEST plus product establishes precedent for commercial execution, with Avantect products extending that framework to additional cancer types.
The next major ASX story will hit our subscribers first
What investors should watch next
The shift from pilot phase to national rollout creates several near-term monitoring points for commercial execution. Uptake data through Sonic and Healius networks will provide initial evidence of market acceptance and clinician adoption rates.
Key metrics to monitor include:
- Clinician adoption rates through Sonic Healthcare and Healius networks as tests become integrated into clinical practice
- Geographic expansion beyond the current three-state coverage for Sonic centres into additional regions
- Revenue contribution from Avantect products in upcoming quarterly financial reports
- Medicare reimbursement pathway developments that could affect patient accessibility and commercial scalability
Patients and clinicians seeking additional information can access resources at earlydetection.com.au, the company’s dedicated information portal.
The commercial traction generated through national rollout will provide visibility into revenue generation potential and demonstrate whether the distribution model can scale effectively through existing pathology infrastructure. The ability to convert national availability into meaningful test volumes will determine the commercial significance of these partnerships beyond the strategic milestone they represent.
Don’t Miss the Next Biotech Breakthrough
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered to your inbox within minutes, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start receiving alerts the moment market-moving announcements hit the ASX.